about
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisHMG CoA reductase inhibitors (statins) for dialysis patientsHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisEffect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.Cardioprotective medication use in hemodialysis patientsStatins in the treatment of chronic heart failure: a systematic reviewOngoing clinical trials of the pleiotropic effects of statinsEffects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trialsEffect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study.Statins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trialsThe Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.Pharmacotherapy of end-stage renal disease.Disorders of lipid metabolism and chronic kidney disease in the elderlyEnd-stage renal diseaseProgression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease.Renal lipid metabolism and lipotoxicity.Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysisChronic kidney disease as a coronary disease equivalent--a comparison with diabetes over a decade.Stroke in chronic kidney disease: prevention and management.Dyslipidemia in children with chronic kidney diseasePromoting scientific collaboration and education in cardiovascular-renal medicine: EURECAM: An ERA-EDTA-based working group.Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial.Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants.Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials.Biomarkers and surrogate endpoints in clinical trialsStatin therapy in patients with chronic kidney disease: to use or not to use.Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients?Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials.Simvastatin: present and future perspectives.The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.The evidence on trial: cholesterol lowering and cancer.Ezetimibe plus simvastatin cardiovascular outcomes study program.Ezetimibe: cholesterol lowering and beyond.Kidney function and estimated vascular risk in patients with primary dyslipidemiaHMG CoA reductase inhibitors and renoprotection: the weight of the evidence.Different effect of hypercholesterolemia on mortality in hemodialysis patients based on coronary artery disease or myocardial infarction.Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA.
P2860
Q24194514-D121989F-B2EA-4F9D-A545-17CF3115F15EQ24198108-180AE86F-0529-4CC6-858B-CEDC15F7A1EEQ24241472-A5F73CDD-E026-4BA9-86A2-D45CF7FFCBB3Q24531203-E4F1CE81-B8F0-40AD-8954-0B40B4039A0AQ28199374-33EE171F-1E40-4DAF-AF51-754905D50A8DQ28200294-0005AA42-D97E-485F-9A50-51740AA1A8D9Q28219321-3D0BAE41-0CD6-4C41-B3EC-A8E5E1669AACQ30841365-5DDFE5A8-D1FD-474C-BC84-EE49A15401E0Q31120569-044414AF-B29F-4389-80EC-C11DC0FA686BQ33244366-1A811774-D850-4F5E-B7F1-50EB03CE6761Q33325660-A4DEB21F-C4B5-4E96-830F-D698B27CD7FDQ33531889-4DFCA4A0-C481-4A14-A4C6-446E1516AD27Q33589563-49A6B511-BBD5-4F69-A19C-F30AA0B9D9A6Q33850437-3B5858E6-684D-4082-B51A-F72302E62F73Q33964855-F50DEF36-D496-4247-B732-B3AEBCF0A4A6Q34457182-6F10208F-DCB4-4B13-AD85-8B35EAFE26F7Q34825296-1631B7F8-E93D-4963-9D8C-D0599324E278Q35030586-5909B09F-ABB0-4B14-82EF-0A903DC22142Q35030617-BA0C27FB-24E3-4763-AE47-19537259F84FQ35153302-9D7BE197-5C7C-45DD-8201-F123EB8802BDQ35568634-F7812B9F-1730-4CF6-AD6C-6DE2ED78854BQ35573867-60FC9474-3C4B-400B-A7D3-F09B54238442Q35674362-937A71AF-94EA-470C-8938-2A41E3BB5C33Q36327959-4BBC36FA-4454-4C57-B1F0-B47406D7959AQ36443751-4AAE02C1-E37A-4995-96E5-1C3817AD7E45Q36552129-29020779-FEB0-4BA9-8E62-4CA96D66F88DQ36558703-6B3DF69C-AA80-4C06-A009-A3949F38EF01Q36566660-8ED4225A-B658-44E5-A88B-D1F728FE7407Q36577189-6098DA12-6055-457F-A420-FCE85C760526Q36711180-8292A36D-B7C2-404D-9E2F-4B596D70A59FQ36835839-075F36F9-E6F4-498F-9153-295EB5B9B218Q36916934-93283EF8-E7D6-4BA1-B28C-8B652F785B0DQ36925157-A9D2313B-2B8C-4D2B-A66F-8D0DADC084BCQ36982051-975437A9-4103-4AA6-87BA-75603F12125CQ37038946-C2AFEE0D-280E-4B14-BB18-811BA3363221Q37134467-B7CD8597-0FA0-4719-BA30-CE5565C3407EQ37245464-12F811BB-38BD-49A7-8D42-6D27D235EEDCQ37362681-173F69F7-0249-4087-A161-E4578BC915FBQ37482995-AFF38CF0-F98C-4D0A-958A-358BC9637E88Q37495281-2C50BA12-B660-4210-A3FD-8F218C079C6F
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Study of Heart and Renal Protection (SHARP).
@ast
Study of Heart and Renal Protection (SHARP).
@en
type
label
Study of Heart and Renal Protection (SHARP).
@ast
Study of Heart and Renal Protection (SHARP).
@en
prefLabel
Study of Heart and Renal Protection (SHARP).
@ast
Study of Heart and Renal Protection (SHARP).
@en
P1476
Study of Heart and Renal Protection (SHARP).
@en
P2093
Colin Baigent
Martin Landry
P304
P356
10.1046/J.1523-1755.63.S84.4.X
P577
2003-05-01T00:00:00Z